Roundtable Discussion: CD19, CD20, BCMA – What is the Optimal Target for Autoimmune Indications?
Time: 9:30 am
day: Day 2
Details:
- Comparing the therapeutic potential of CD19, CD20, and BCMA as targets for autoimmune diseases, considering immune cell populations and disease pathophysiology
- Evaluating safety and efficacy profiles of targeting these antigens, including off-target effects, potential for immune depletion, and long-term durability
- Exploring optimal strategies for T-cell engager development, including antigen selection, dosing regimens, and combination therapies to achieve targeted immune modulation
